Dabigatran: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), CIPM (Spain) and HAS (France), among others, recommended or restricted dabigatran, while CONITEC (Brazil) did not recommend it.
The file has been open for more than a decade: 17 years separate the first record, 9 Jun 2008 at SMC (Scotland), from the most recent, 19 Jun 2025 at CIPM (Spain).
TLV (Sweden) changed its position: restricted on 22 Dec 2010, recommended by 1 Dec 2011.
No assessment is on file from PBAC (Australia) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for dabigatran, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 2 of 23 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for dabigatran by the agencies that label one in English (AWMSG, NICE and SMC).
SMC (Scotland) was first to assess dabigatran, on 9 Jun 2008; CIPM (Spain) did not open a file until 21 Feb 2024 — an unusually long tail of 15.7 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 12 years in total.
8 of the 8 agencies here assessed dabigatran more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for dabigatran.
The full ledger for dabigatran reads 10 recommended, 4 other, 3 restricted and 3 not recommended, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 19 Jun 2025 | Indicaciones terapéuticas autorizadas y financiadas: Prevención del ictus y de la embolia sistémica en pacientes adultos… | excluded from SNS provision · art. 92 e | source |
| AWMSG (Wales) | 10 Dec 2021 | Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from 8 years to l… | recommended (licence extension for paediatric use) | source |
| CONITEC (Brazil) | 1 Oct 2020 | Prevenção do acidente vascular cerebral em pacientes acima de 60 anos com fibrilação atrial não valvar que não conseguem… | not incorporated | source |
| PHARMAC (New Zealand) | 24 Sep 2020 | Prevention of stroke and systemic embolism in atrial fibrillation | PTAC advice: Low · decision reached | source |
| HAS (France) | 24 Jan 2018 | Re-assessment of SMR and ASMR | ASMR V | source |
18 further decisions for dabigatran, across 8 agencies, are not shown here. They link to 13 further source documents.
Related molecules
- rivaroxaban — same ATC class B01A — Antithrombotics
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
- ticagrelor — same ATC class B01A — Antithrombotics
- clopidogrel — same ATC class B01A — Antithrombotics
Coverage: 23 decisions for dabigatran from 8 agencies, 2008 to 2025. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.